Cytokinetics CYTK Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -605.1%+2,338pp | -695.4%+2,207pp | -656.9%+15,641pp | -638%+15,510pp | -2,943.3%+10,329pp | |
| Net margin | -784%+2,417pp | -891.6%+2,300pp | -862.2%+17,044pp | -707.2%+16,692pp | -3,201.5%+10,940pp | |
| EBITDA margin | -594.5%+2,299pp | -683.9%+2,167pp | -645.9%+15,233pp | -627%+15,109pp | -2,893.9%+10,048pp | |
| Free cash flow margin | -518.8%+1,602pp | -607.5%+1,557pp | -519.9%+12,125pp | -511.7%+12,292pp | -2,120.8%+9,142pp | |
| Returns | ||||||
| Return on assets | -65.4%-6.0pp | -55.5%-2.6pp | -52.4%+0.6pp | -44.1%+3.2pp | -59.4%+3.1pp | |
| Efficiency | ||||||
| Asset turnover | 0.1×+0.1× | 0.1×0.0× | 0.1×+0.1× | 0.1×+0.1× | 0×0.0× | |
| Liquidity | ||||||
| Current ratio | 4.2×-1.8× | 4.5×-1.6× | 6.9×-2.4× | 6.8×-3.6× | 6×-1.2× | |
| Quick ratio | 4.2×-1.8× | 4.5×-1.6× | 6.9×-2.4× | 6.8×-3.6× | 6×-1.2× | |
| Cash ratio | 0.7×+0.2× | 0.6×+0.1× | 1.6×+1.2× | 0.6×-1.3× | 0.5×-0.9× | |
| Leverage | ||||||
| Debt-to-assets | 0.3×+0.1× | 0.3×+0.1× | 0.2×0.0× | 0.2×+0.1× | 0.2×-0.1× | |
| Interest coverage | -12.5×+1.8× | -13.4×+0.8× | -14.2×+0.4× | -14.5×+0.4× | -14.3×+3.2× | |
| Per Share | ||||||
| Book value per share | -$6.71-198% | -$5.49-354% | -$4.34-3,575% | -$3.09-411% | -$2.25+42.2% | |
| Valuation | ||||||
| Market capitalization | $8.12B+70.6% | $7.77B+39.9% | $6.58B+5.9% | $3.99B-37.2% | $4.76B-34.1% | |
| Enterprise value | $8.41B+70.7% | $8.06B+41.6% | $6.66B+4.0% | $4.22B-34.1% | $4.92B-32.6% | |
| Price / sales | 76.7×-171× | 88.2×-212× | 75.4×-1,855× | 46.5×-1,979× | 247.6×-1,677× | |
| EV / sales | 79.4×-177× | 91.6×-217× | 76.3×-1,913× | 49.2×-1,992× | 256.2×-1,691× | |
| Free cash flow yield | -6.8%+1.8pp | -6.9%+0.3pp | -6.9%-0.3pp | -11%-4.7pp | -8.6%-2.7pp | |
| Earnings yield | -10.2%+2.7pp | -10.1%+0.5pp | -11.4%-2.2pp | -15.2%-6.6pp | -12.9%-5.6pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Cytokinetics's ratios come from?
- Every ratio is computed from Cytokinetics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
